New insights into the anti-diabetic actions of metformin: from the liver to the gut

References

• Slotta KH, Tschesche E. Über Biguanide TR II. Die blutzuckersenkende Wirkung der Biguanide. Ber Dtsch Chem Ges. 1929;62:1398–1405.
   Google Scholar
• Inzucchi SE, Lipska KJ, Mayo H, et al. Metformin in patients with type 2 diabetes and kidney disease: a systematic review. JAMA. 2014;312(24):2668–2675.
   PubMed Web of Science ®Google Scholar
• Group U. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) group. Lancet. 1998;352(9131):837–853.
   PubMed Web of Science ®Google Scholar
• Selvin E, Bolen S, Yeh HC, et al. Cardiovascular outcomes in trials of oral diabetes medications: a systematic review. Arch Intern Med. 2008;168(19):2070–2080.
   PubMedGoogle Scholar
• Andujar-Plata P, Pi-Sunyer X, Laferrere B. Metformin effects revisited. Diabetes Res Clin Pract. 2012;95(1):1–9.
   PubMed Web of Science ®Google Scholar
• Stumvoll M, Nurjhan N, Perriello G, et al. Metabolic effects of metformin in non-insulin-dependent diabetes mellitus. N Engl J Med. 1995;333(9):550–554.
   PubMed Web of Science ®Google Scholar
• Tucker GT, Casey C, Phillips PJ, et al. Metformin kinetics in healthy subjects and in patients with diabetes mellitus. Br J Clin Pharmacol. 1981;12(2):235–246.
   PubMed Web of Science ®Google Scholar
• Graham GG, Punt J, Arora M, et al. Clinical pharmacokinetics of metformin. Clin Pharmacokinet. 2011;50(2):81–98.
   PubMed Web of Science ®Google Scholar
• He L, Wondisford FE. Metformin action: concentrations matter. Cell Metab. 2015;21(2):159–162.
   PubMed Web of Science ®Google Scholar
• Buse JB, DeFronzo RA, Rosenstock J, et al. The primary glucose-lowering effect of metformin resides in the gut, not the circulation: results from short-term pharmacokinetic and 12-week dose-ranging studies. Diabetes Care. 2016;39(2):198–205.
   PubMed Web of Science ®Google Scholar
• Wilcock C, Bailey CJ. Accumulation of metformin by tissues of the normal and diabetic mouse. Xenobiotica. 1994;24(1):49–57.
   PubMed Web of Science ®Google Scholar
• Bailey CJ, Wilcock C, Scarpello JH. Metformin and the intestine. Diabetologia. 2008;51(8):1552–1553.
   PubMed Web of Science ®Google Scholar
• Oh J, Chung H, Park SI, et al. Inhibition of the MATE transporter by pyrimethamine increases the plasma concentration of metformin but does not increase anti-hyperglycaemic activity in humans. Diabetes Obes Metab. 2016;18(1):104–108.
   PubMed Web of Science ®Google Scholar
• Morrissey KM, Stocker SL, Chen EC, et al. The effect of nizatidine, a MATE2K selective inhibitor, on the pharmacokinetics and pharmacodynamics of metformin in healthy volunteers. Clin Pharmacokinet. 2016;55(4):495–506.
   PubMed Web of Science ®Google Scholar
• Owen MR, Doran E, Halestrap AP. Evidence that metformin exerts its anti-diabetic effects through inhibition of complex 1 of the mitochondrial respiratory chain. Biochem J. 2000;348(Pt 3):607–614.
   PubMed Web of Science ®Google Scholar
• El-Mir MY, Nogueira V, Fontaine E, et al. Dimethylbiguanide inhibits cell respiration via an indirect effect targeted on the respiratory chain complex I. J Biol Chem. 2000;275(1):223–228.
   PubMed Web of Science ®Google Scholar
• Zhou G, Myers R, Li Y, et al. Role of AMP-activated protein kinase in mechanism of metformin action. J Clin Invest. 2001;108(8):1167–1174.
   PubMed Web of Science ®Google Scholar
• Shaw RJ, Lamia KA, Vasquez D, et al. The kinase LKB1 mediates glucose homeostasis in liver and therapeutic effects of metformin. Science. 2005;310(5754):1642–1646.
   PubMed Web of Science ®Google Scholar
• Caton PW, Nayuni NK, Kieswich J, et al. Metformin suppresses hepatic gluconeogenesis through induction of SIRT1 and GCN5. J Endocrinol. 2010;205(1):97–106.
   PubMed Web of Science ®Google Scholar
• He L, Sabet A, Djedjos S, et al. Metformin and insulin suppress hepatic gluconeogenesis through phosphorylation of CREB binding protein. Cell. 2009;137(4):635–646.
   PubMed Web of Science ®Google Scholar
• Foretz M, Hebrard S, Leclerc J, et al. Metformin inhibits hepatic gluconeogenesis in mice independently of the LKB1/AMPK pathway via a decrease in hepatic energy state. J Clin Invest. 2010;120(7):2355–2369.
   PubMed Web of Science ®Google Scholar
• Fullerton MD, Galic S, Marcinko K, et al. Single phosphorylation sites in Acc1 and Acc2 regulate lipid homeostasis and the insulin-sensitizing effects of metformin. Nat Med. 2013;19(12):1649–1654.
   PubMed Web of Science ®Google Scholar
• Zhao W, Li A, Feng X, et al. Metformin and resveratrol ameliorate muscle insulin resistance through preventing lipolysis and inflammation in hypoxic adipose tissue. Cell Signal. 2016;28(9):1401–1411.
   PubMed Web of Science ®Google Scholar
• Miller RA, Chu Q, Xie J, et al. Biguanides suppress hepatic glucagon signalling by decreasing production of cyclic AMP. Nature. 2013;494(7436):256–260.
   PubMed Web of Science ®Google Scholar
• Wu T, Ma J, Bound MJ, et al. Effects of sitagliptin on glycemia, incretin hormones, and antropyloroduodenal motility in response to intraduodenal glucose infusion in healthy lean and obese humans and patients with type 2 diabetes treated with or without metformin. Diabetes. 2014;63(8):2776–2787.
   PubMed Web of Science ®Google Scholar
• Gu W, Yan H, Winters KA, et al. Long-term inhibition of the glucagon receptor with a monoclonal antibody in mice causes sustained improvement in glycemic control, with reversible alpha-cell hyperplasia and hyperglucagonemia. J Pharmacol Exp Ther. 2009;331(3):871–881.
   PubMed Web of Science ®Google Scholar
• Madiraju AK, Erion DM, Rahimi Y, et al. Metformin suppresses gluconeogenesis by inhibiting mitochondrial glycerophosphate dehydrogenase. Nature. 2014;510(7506):542–546.
   PubMed Web of Science ®Google Scholar
• Sum CF, Webster JM, Johnson AB, et al. The effect of intravenous metformin on glucose metabolism during hyperglycaemia in type 2 diabetes. Diabet Med. 1992;9(1):61–65.
   PubMed Web of Science ®Google Scholar
• Cao J, Meng S, Chang E, et al. Low concentrations of metformin suppress glucose production in hepatocytes through AMP-activated protein kinase (AMPK). J Biol Chem. 2014;289(30):20435–20446.
   PubMed Web of Science ®Google Scholar
• Zhang CS, Li M, Ma T, et al. Metformin activates AMPK through the lysosomal pathway. Cell Metab. 2016;24(4):521–522.
   PubMed Web of Science ®Google Scholar
• Chandel NS, Avizonis D, Reczek CR, et al. Are metformin doses used in murine cancer models clinically relevant? Cell Metab. 2016;23(4):569–570.
   PubMed Web of Science ®Google Scholar
• Shu Y, Sheardown SA, Brown C, et al. Effect of genetic variation in the organic cation transporter 1 (OCT1) on metformin action. J Clin Invest. 2007;117(5):1422–1431.
   PubMed Web of Science ®Google Scholar
• Zhou K, Donnelly LA, Kimber CH, et al. Reduced-function SLC22A1 polymorphisms encoding organic cation transporter 1 and glycemic response to metformin: a GoDARTS study. Diabetes. 2009;58(6):1434–1439.
   PubMed Web of Science ®Google Scholar
• Stepensky D, Friedman M, Raz I, et al. Pharmacokinetic-pharmacodynamic analysis of the glucose-lowering effect of metformin in diabetic rats reveals first-pass pharmacodynamic effect. Drug Metab Dispos. 2002;30(8):861–868.
   PubMed Web of Science ®Google Scholar
• Ikeda T, Iwata K, Murakami H. Inhibitory effect of metformin on intestinal glucose absorption in the perfused rat intestine. Biochem Pharmacol. 2000;59(7):887–890.
   PubMed Web of Science ®Google Scholar
• Wilcock C, Bailey CJ. Reconsideration of inhibitory effect of metformin on intestinal glucose absorption. J Pharm Pharmacol. 1991;43(2):120–121.
   PubMed Web of Science ®Google Scholar
• Sakar Y, Meddah B, Faouzi MA, et al. Metformin-induced regulation of the intestinal D-glucose transporters. J Physiol Pharmacol. 2010;61(3):301–307.
   PubMed Web of Science ®Google Scholar
• Lenzen S, Lortz S, Tiedge M. Effect of metformin on SGLT1, GLUT2, and GLUT5 hexose transporter gene expression in small intestine from rats. Biochem Pharmacol. 1996;51(7):893–896.
   PubMed Web of Science ®Google Scholar
• Wu T, Xie C, Wu H, et al. Metformin reduces the rate of small intestinal glucose absorption in type 2 diabetes. Diabetes Obes Metab. 2016. doi:10.1111/dom.12812. [Epub ahead of print].
   Web of Science ®Google Scholar
• Gontier E, Fourme E, Wartski M, et al. High and typical 18F-FDG bowel uptake in patients treated with metformin. Eur J Nucl Med Mol Imaging. 2008;35(1):95–99.
   PubMed Web of Science ®Google Scholar
• Wilcock C, Bailey CJ. Sites of metformin-stimulated glucose metabolism. Biochem Pharmacol. 1990;39(11):1831–1834.
   PubMed Web of Science ®Google Scholar
• Bailey CJ, Wilcock C, Day C. Effect of metformin on glucose metabolism in the splanchnic bed. Br J Pharmacol. 1992;105(4):1009–1013.
   PubMed Web of Science ®Google Scholar
• Wu T, Rayner CK, Horowitz M. Incretins. Handb Exp Pharmacol. 2016;233:137–171.
   PubMedGoogle Scholar
• Wu T, Thazhath SS, Bound MJ, et al. Mechanism of increase in plasma intact GLP-1 by metformin in type 2 diabetes: stimulation of GLP-1 secretion or reduction in plasma DPP-4 activity? Diabetes Res Clin Pract. 2014;106(1):e3–e6.
   PubMed Web of Science ®Google Scholar
• Mulherin AJ, Oh AH, Kim H, et al. Mechanisms underlying metformin-induced secretion of glucagon-like peptide-1 from the intestinal L cell. Endocrinology. 2011;152(12):4610–4619.
   PubMed Web of Science ®Google Scholar
• Cuthbertson J, Patterson S, O’Harte FP, et al. Addition of metformin to exogenous glucagon-like peptide-1 results in increased serum glucagon-like peptide-1 concentrations and greater glucose lowering in type 2 diabetes mellitus. Metabolism. 2011;60(1):52–56.
   PubMed Web of Science ®Google Scholar
• Bahne E, Hansen M, Bronden A, et al. Involvement of glucagon-like peptide-1 in the glucose-lowering effect of metformin. Diabetes Obes Metab. 2016;18(10):655–661.
   Web of Science ®Google Scholar
• Kim MH, Jee JH, Park S, et al. Metformin enhances glucagon-like peptide 1 via cooperation between insulin and Wnt signaling. J Endocrinol. 2014;220(2):117–128.
   PubMed Web of Science ®Google Scholar
• Maida A, Lamont BJ, Cao X, et al. Metformin regulates the incretin receptor axis via a pathway dependent on peroxisome proliferator-activated receptor-alpha in mice. Diabetologia. 2011;54(2):339–349.
   PubMed Web of Science ®Google Scholar
• Duca FA, Cote CD, Rasmussen BA, et al. Metformin activates a duodenal Ampk-dependent pathway to lower hepatic glucose production in rats. Nat Med. 2015;21(5):506–511.
   PubMed Web of Science ®Google Scholar
• Hansen M, Bahne E, Sonne DP, et al. The acute glucose-lowering effect of metformin in patients with type 2 diabetes is partly glucagon-like peptide-1-dependent. Diabetologia. 2015;58(Suppl):S110.
   Google Scholar
• Eissele R, Goke R, Willemer S, et al. Glucagon-like peptide-1 cells in the gastrointestinal tract and pancreas of rat, pig and man. Eur J Clin Invest. 1992;22(4):283–291.
   PubMed Web of Science ®Google Scholar
• DeFronzo RA, Buse JB, Kim T, et al. Once-daily delayed-release metformin lowers plasma glucose and enhances fasting and postprandial GLP-1 and PYY: results from two randomised trials. Diabetologia. 2016;59(8):1645–1654.
   PubMed Web of Science ®Google Scholar
• Caspary WF, Creutzfeldt W. Inhibition of bile salt absorption by blood-sugar lowering biguanides. Diabetologia. 1975;11(2):113–117.
   PubMed Web of Science ®Google Scholar
• Scarpello JH, Hodgson E, Howlett HC. Effect of metformin on bile salt circulation and intestinal motility in type 2 diabetes mellitus. Diabet Med. 1998;15(8):651–656.
   PubMed Web of Science ®Google Scholar
• Rudling M, Camilleri M, Graffner H, et al. Specific inhibition of bile acid transport alters plasma lipids and GLP-1. BMC Cardiovasc Disord. 2015;15:75.
   PubMed Web of Science ®Google Scholar
• Sonne DP, Knop FK., Comment on Xu, et al.. Effects of metformin on metabolite profiles and LDL cholesterol in patients with type 2 diabetes. Diabetes Care. 2015;38:1858–1867, e215.
   PubMed Web of Science ®Google Scholar
• Nguyen A, Bouscarel B. Bile acids and signal transduction: role in glucose homeostasis. Cell Signal. 2008;20(12):2180–2197.
   PubMed Web of Science ®Google Scholar
• Sonne DP, Hare KJ, Martens P, et al. Postprandial gut hormone responses and glucose metabolism in cholecystectomized patients. Am J Physiol Gastrointest Liver Physiol. 2012;304(4):G413–G419.
   PubMed Web of Science ®Google Scholar
• Pournaras DJ, Glicksman C, Vincent RP, et al. The role of bile after roux-en-Y gastric bypass in promoting weight loss and improving glycaemic control. Endocrinology. 2012;153(8):3613–3619.
   PubMed Web of Science ®Google Scholar
• Ferrannini E, Camastra S, Astiarraga B, et al. Increased bile acid synthesis and deconjugation after biliopancreatic diversion. Diabetes. 2015;64(10):3377–3385.
   PubMed Web of Science ®Google Scholar
• Zhang X, Liu T, Wang Y, et al. Comparative effects of bile diversion and duodenal-jejunal bypass on glucose and lipid metabolism in male diabetic rats. Obes Surg. 2016;26(7):1565–1575.
   PubMed Web of Science ®Google Scholar
• Ma K, Saha PK, Chan L, et al. Farnesoid X receptor is essential for normal glucose homeostasis. The Journal of Clinical Investigation. 2006;116(4):1102–1109.
   PubMed Web of Science ®Google Scholar
• Reimann F, Habib AM, Tolhurst G, et al. Glucose sensing in L cells: a primary cell study. Cell Metab. 2008;8(6):532–539.
   PubMed Web of Science ®Google Scholar
• Pham H, Hui H, Morvaridi S, et al. A bitter pill for type 2 diabetes? The activation of bitter taste receptor TAS2R38 can stimulate GLP-1 release from enteroendocrine L-cells. Biochem Biophys Res Commun. 2016;475(3):295–300.
   PubMed Web of Science ®Google Scholar
• Wu T, Bound MJ, Standfield SD, et al. Effects of rectal administration of taurocholic acid on glucagon-like peptide-1 and peptide YY secretion in healthy humans. Diabetes Obes Metab. 2013;15(5):474–477.
   PubMed Web of Science ®Google Scholar
• Adrian TE, Gariballa S, Parekh KA, et al. Rectal taurocholate increases L cell and insulin secretion, and decreases blood glucose and food intake in obese type 2 diabetic volunteers. Diabetologia. 2012;55(9):2343–2347.
   PubMed Web of Science ®Google Scholar
• Wu T, Bound MJ, Standfield SD, et al. Effects of taurocholic acid on glycemic, glucagon-like peptide-1, and insulin responses to small intestinal glucose infusion in healthy humans. J Clin Endocrinol Metab. 2013;98(4):E718–E722.
   PubMed Web of Science ®Google Scholar
• Islam KB, Fukiya S, Hagio M, et al. Bile acid is a host factor that regulates the composition of the cecal microbiota in rats. Gastroenterology. 2011;141(5):1773–1781.
   PubMed Web of Science ®Google Scholar
• Nagpal R, Kumar M, Yadav AK, et al. Gut microbiota in health and disease: an overview focused on metabolic inflammation. Benef Microbes. 2016;7(2):181–194.
   PubMed Web of Science ®Google Scholar
• Shin NR, Lee JC, Lee HY, et al. An increase in the Akkermansia spp. population induced by metformin treatment improves glucose homeostasis in diet-induced obese mice. Gut. 2014;63(5):727–735.
   PubMed Web of Science ®Google Scholar
• Collado MC, Derrien M, Isolauri E, et al. Intestinal integrity and Akkermansia muciniphila, a mucin-degrading member of the intestinal microbiota present in infants, adults, and the elderly. Appl Environ Microbiol. 2007;73(23):7767–7770.
   PubMed Web of Science ®Google Scholar
• Forslund K, Hildebrand F, Nielsen T, et al. Disentangling type 2 diabetes and metformin treatment signatures in the human gut microbiota. Nature. 2015;528(7581):262–266.
   PubMed Web of Science ®Google Scholar
• Phillips LK, Deane AM, Jones KL, et al. Gastric emptying and glycaemia in health and diabetes mellitus. Nat Rev Endocrinol. 2015;11(2):112–128.
   PubMed Web of Science ®Google Scholar
• Eisner M, Berger W. Biguanides and gastric emptying in man. Digestion. 1971;4(5):309–313.
   PubMed Web of Science ®Google Scholar
• Naimi M, Tsakiridis T, Stamatatos TC, et al. Increased skeletal muscle glucose uptake by rosemary extract through AMPK activation. Appl Physiol Nutr Meta. 2015;40(4):407–413.
   PubMed Web of Science ®Google Scholar
• Gunton JE, Delhanty PJ, Takahashi S, et al. Metformin rapidly increases insulin receptor activation in human liver and signals preferentially through insulin-receptor substrate-2. J Clin Endocrinol Metab. 2003;88(3):1323–1332.
   PubMed Web of Science ®Google Scholar
• Luna V, Casauban L, Sajan MP, et al. Metformin improves atypical protein kinase C activation by insulin and phosphatidylinositol-3,4,5-(PO4)3 in muscle of diabetic subjects. Diabetologia. 2006;49(2):375–382.
   PubMed Web of Science ®Google Scholar
• Natali A, Baldeweg S, Toschi E, et al. Vascular effects of improving metabolic control with metformin or rosiglitazone in type 2 diabetes. Diabetes Care. 2004;27(6):1349–1357.
   PubMed Web of Science ®Google Scholar
• Ciaraldi TP, Aroda V, Mudaliar SR, et al. Inflammatory cytokines and chemokines, skeletal muscle and polycystic ovary syndrome: effects of pioglitazone and metformin treatment. Metabolism. 2013;62(11):1587–1596.
   PubMed Web of Science ®Google Scholar
• Ali S, Fonseca V. Overview of metformin: special focus on metformin extended release. Expert Opin Pharmacother. 2012;13(12):1797–1805.
   PubMed Web of Science ®Google Scholar
• Bytzer P, Talley NJ, Jones MP, et al. Oral hypoglycaemic drugs and gastrointestinal symptoms in diabetes mellitus. Aliment Pharmacol Ther. 2001;15(1):137–142.
   PubMed Web of Science ®Google Scholar
• Kojima S, Tohei A, Anzai N. A role for endogenous peptide YY in tachykinin NK(2) receptor-triggered 5-HT release from guinea pig isolated colonic mucosa. Br J Pharmacol. 2012;167(6):1362–1368.
   PubMed Web of Science ®Google Scholar
• Wu T, Rayner CK, Young RL, et al. Gut motility and enteroendocrine secretion. Curr Opin Pharmacol. 2013;13(6):928–934.
   PubMed Web of Science ®Google Scholar
• Hostalek U, Gwilt M, Hildemann S. Therapeutic use of metformin in prediabetes and diabetes prevention. Drugs. 2015;75(10):1071–1094.
   PubMed Web of Science ®Google Scholar
• Brown JB, Conner C, Nichols GA. Secondary failure of metformin monotherapy in clinical practice. Diabetes Care. 2010;33(3):501–506.
   PubMed Web of Science ®Google Scholar